Circulating tumor cells in colorectal cancer patients

Cancer Treatment Reviews

Volumn 39, Issue 7, 2013, Pages 759-772

  Torino, Francesco ^a   Bonmassar, Enzo ^a,b   Bonmassar, Laura ^c   De Vecchis, Liana ^a   Barnabei, Agnese ^d   Zuppi, Cecilia ^e   Capoluongo, Ettore ^e   Aquino, Angelo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

Circulating tumor cells; Colorectal cancer; Predictive factor; Prognostic factor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CD45 ANTIGEN; CETUXIMAB; CYTOKERATIN; EPITHELIAL CELL ADHESION MOLECULE; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CIRCULATING TUMOR CELL; COLORECTAL CANCER; DISEASE SEVERITY; FOLLOW UP; HUMAN; IMMUNOCYTOCHEMISTRY; LASER SCANNING CYTOMETRY; LIVER METASTASIS; NONHUMAN; PREDICTIVE VALUE; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SURVIVAL RATE;

CIRCULATING TUMOR CELLS; COLORECTAL CANCER; PREDICTIVE FACTOR; PROGNOSTIC FACTOR;

COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881542996     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.12.007     Document Type: Review

References (171)

1. World Cancer Research Fund and American Institute for Cancer Research Food Nutrition, physical activity, and the prevention of cancer: a global perspective 2007, American Institute for Cancer Research, Washington, (DC).
2. Hayashi M., Inoue Y., Komeda K., et al. Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg 2010, 10:27.
3. Roth A.D., Tejpar S., Delorenzi M., et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010, 28:466-474.
4. Salazar R., Roepman P., Capella G., et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011, 29:17-24.
5. Vilar E., Gruber S.B. Microsatellite instability in colorectal cancer: the stable evidence. Nat Rev Clin Oncol 2010, 7:153-162.
6. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005, 23:7332-7341.
7. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
8. Sargent D.J., Marsoni S., Monges G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010, 28:3219-3226.
9. Paterlini-Brechot P., Benali N.L. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007, 253:180-204.
10. Tibbe A.G.J., Miller M.C., Terstappen L.W. Statistical considerations for enumeration of circulating tumor cells. Cytometry 2007, 71:154-162.
11. Glaves D. Correlation between circulating cancer cells and incidence of metastases. Br J Cancer 1983, 48:665-673.
12. Allard W.J., Matera J., Miller M.C., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897-6904.
13. Ashworth T.R. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med J Aust 1869, 14:146-149.
14. Pantel K., Brakenhoff R.H. Dissecting the metastatic cascade. Nat Rev Cancer 2004, 4:448-456.
15. Dotan E., Cohen S.J., Alpaugh K.R., Meropol N.J. Circulating tumor cells: evolving evidence and future challenges. Oncologist 2009, 14:1070-1082.
16. Alunni-Fabbroni M., Sandri M.T. Circulating tumour cells in clinical practice. Methods of detection and possible characterization. Methods 2010, 50:289-297.
17. Allen J.E., El-Deiry W.S. Circulating tumor cells and colorectal cancer. Curr Colorectal Cancer Rep 2010, 6:212-220. 10.1007/s11888-010-0069-7.
18. Balic M., Lin H., Williams A., Datar R.H., Cote R.J. Progress in circulating tumor cell capture and analysis: implications for cancer management. Expert Rev Mol Diagn 2012, 12:303-312.
19. Bednarz-Knoll N., Alix-Panabières C., Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res 2011, 13:228. 10.1186/bcr2940.
20. Pantel K., Brakenhoff R.H., Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008, 8:329-340.
21. Miller S., Steele S. Novel molecular screening approaches in colorectal cancer. J Surg Oncol 2012, 105:459-467.
22. http://www.accessdata.fda.gov/cdrh_docs/pdf3/k031588.pdf.
23. Nagrath S., Sequist L.V., Maheswaran S., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450:1235-1239.
24. Hsieh H.B., Marrinucci D., Bethel K., et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006, 21:1893-1899.
25. Berinstein N.L. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 2002, 20:2197-2207.
26. Gerhard M., Juhl H., Kalthoff H., Schreiber H.W., Wagener C., Neumaier M. Specific detection of carcinoembryonic antigen expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994, 12:725-729.
27. Mori M., Mimori K., Ueo H., et al. Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription-polymerase chain reaction in patients with gastrointestinal or breast carcinomas. J Clin Oncol 1998, 16:128-132.
28. Mori M., Mimori K., Ueo H., et al. Molecular detection of circulating solid carcinoma cells in the peripheral blood: the concept of early systemic disease. Int J Cancer 1996, 68:739-743.
29. Liefers G.J., Cleton-Jansen A.M., Van de Velde C.J.H., et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998, 339:223-228.
30. Hampton R., Walker M., Marshall J., Juhl H. Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cells. Oncogene 2002, 21:7817-7823.
31. Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999, 9:67-81.
32. Tien Y.W., Lee P.H., Wang S.M., Hsu S.M., Chang K.J. Simultaneous detection of colonic epithelial cells in portal venous and peripheral blood during colorectal cancer surgery. Dis Colon Rectum 2002, 45:23-29.
33. Nakagoe T., Sawai T., Tsuji T., et al. Prognostic value of serum sialyl Lewis(a), sialyl Lewis(x) and sialyl Tn antigens in blood from the tumor drainage vein of colorectal cancer patients. Tumour Biol 2001, 22:115-122.
34. Shetye J.D., Liljefors M.L., Emdin S.O., et al. Spectrum of cytokeratin-positive cells in the bone marrows of colorectal carcinoma patients. Anticancer Res 2004, 24:2375-2383.
35. Gauthier L.R., Granotier C., Soria J.C., et al. Detection of circulating carcinoma cells by telomerase activity. Br J Cancer 2001, 84:631-635.
36. Hardingham J.E., Kotasek D., Sage R.E., Eaton M.C., Pascoe V.H., Dobrovic A. Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease. Mol Med 1995, 1:789-794.
37. Yang M.J., Chiu H.H., Wang H.M., et al. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann Surg Oncol 2010, 17:624-633.
38. Aquino A., Formica V., Prete S.P., et al. Drug- induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res 2004, 49:383-396.
39. Aquino A., Prete S.P., Balduzzi A., et al. Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells. Int J Cancer 2002, 100:119-121.
40. Bonmassar L., Fossile E., Scoppola A., et al. Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies. Anticancer Res 2010, 30:4721-4730.
41. Negin B.P., Cohen S.J. Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol 2010, Feb 9. 10.1007/s11864-010-0115-3.
42. Hiraiwa K., Takeuchi H., Hasegawa H., et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol 2008, 15:3092-3100.
43. Moreno J.G., et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 2001, 58(3):386-392.
44. Cristofanilli M., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351(8):781-791.
45. Molnar B., Ladanyi A., Tanko L., Sréter L., Tulassay Z. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 2001, 7:4080-4085.
46. Wong S.C., Chan C.M., Ma B.B., et al. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res 2009, 15:1005-1012.
47. Rahbari N.N., Bork U., Kircher A., et al. Compartmental differences of circulating tumor cells in colorectal cancer. Ann Surg Oncol 2012, 19:2195-2202. 10.1245/s10434-011-2178-1.
48. Sastre J., Maestro M.L., Puente J., et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 2008, 19:935-938.
49. Cohen S.J., Alpaugh R.K., Gross S., et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006, 6:125-132.
50. Molnar B., Floro L., Sipos F., Toth B., Sreter L., Tulassay Z. Elevation in peripheral blood circulating tumor cell number correlates with macroscopic progression in UICC stage IV colorectal cancer patients. Dis Markers 2008, 24:141-150.
51. Rahbari N.N., Aigner M., Thorlund K., et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 2010, 138:1714-1726.
52. Fujita S., Kudo N., Akasu T., et al. Detection of cytokeratin 19 and 20 mRNA in peripheral and mesenteric blood from colorectal cancer patients and their prognosis. Int J Colorectal Dis 2001, 16:141-146.
53. Ito S., Nakanishi H., Hirai T., et al. Quantitative detection of CEA expressing free tumor cells in the peripheral blood of colorectal cancer patients during surgery with real-time RT-PCR on a Light-Cycler. Cancer Lett 2002, 183:195-203.
54. Guller U., Zajac P., Schnider A., et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002, 236:768-776.
55. Akashi A., Komuta K., Haraguchi M., et al. Carcinoembryonic antigen mRNA in the mesenteric vein is not a predictor of hepatic metastasis in patients with resectable colorectal cancer: a long-term study. Dis Colon Rectum 2003, 46:1653-1658.
56. Bessa X., Pinol V., Castelli-Bel S., et al. Prognostic value of postoperative detection of blood circulating tumor cells in patients with colorectal cancer operated for cure. Ann Surg 2003, 237:368-375.
57. Bessa X., Elizalde J.I., Boix L., et al. Lack of prognostic influence of circulating tumor cells in peripheral blood of patients with colorectal cancer. Gastroenterology 2001, 120:1084-1092.
58. Bosch B., Guller U., Schnider A., et al. Perioperative detection of disseminated tumor cells is an independent prognostic factor in patients with colorectal cancer. Br J Surg 2003, 90:882-888.
59. Sadahiro S., Suzuki T., Ishikawa K., et al. Detection of carcinoembryonic antigen messenger RNA-expressing cells in portal and peripheral blood during surgery does not influence relapse in colorectal cancer. Ann Surg Oncol 2005, 12:988-994.
60. Iinuma H., Okinaga K., Egami H., et al. Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int J Oncol 2006, 28:297-306.
61. Koch M., Kienle P., Kastrati D., et al. Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int J Cancer 2006, 118:3072-3077.
62. Lloyd J.M., McIver C.M., Stephenson S.A., et al. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res 2006, 12:417-423.
63. Allen-Mersh T.G., McCullough T.K., Patel H., et al. Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br J Surg 2007, 94:96-105.
64. Sadahiro S., Suzuki T., Maeda Y., et al. Detection of carcinoembryonic antigen messenger RNA-expressing cells in peripheral blood 7days after curative surgery is a novel prognostic factor in colorectal cancer. Ann Surg Oncol 2007, 14:1092-1098.
65. Koyanagi K., Bilchik A.J., Saha S., et al. Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin Cancer Res 2008, 14:7391-7396.
66. Uen Y.H., Lu C.Y., Tsai H.L., et al. Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann Surg Oncol 2008, 15:2120-2128.
67. Steinert R., Hantschick M., Vieth M., et al. Influence of subclinical tumor spreading on survival after curative surgery for colorectal cancer. Arch Surg 2008, 143:122-128.
68. Garrigós N., Gallego J., Guillén-Ponce C., et al. Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study. Clin Transl Oncol 2010, 12:142-147.
69. Peach G., Kim C., Zacharakis E., Purkayastha S., Ziprin P. Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer 2010, 102:1327-1334.
70. Thorsteinsson M., Jess P. The clinical significance of circulating tumor cells in non-metastatic colorectal cancer - A review. Eur J Surg Oncol 2011, 37:1-7. 10.1016/j.ejso.2011.01.025.
71. Mescoli C., Albertoni L., Pucciarelli S., Giacomelli L., Russo V.M., Fassan M., et al. Isolated tumor cells in regional lymph nodes as relapse predictors in stage I and II colorectal cancer. J Clin Oncol 2012, 30:965-971.
72. Rahbari N.N., Bork U., Motschall E., et al. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2012, 30:60-70. 10.1200/JCO.2011.36.9504.
73. Lu C.Y., Uen Y.H., Tsai H.L., et al. Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse. Br J Cancer 2011, 104:1178-1184.
74. Katsuno H., Zacharakis E., Aziz O., et al. Does the presence of circulating tumor cells in the venous drainage of curative colorectal cancer resections determine prognosis? A meta-analysis. Ann Surg Oncol 2008, 15:3083-3091. 10.1245/s10434-008-0131-8.
75. Lankiewicz S., Zimmermann S., Hollmann C., Hillemann T., Greten T.F. Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Mol Oncol 2008, 2:349-355.
76. Cohen S.J., Punt C.J.A., Iannotti N., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:3213-3221.
77. Cohen S.J., Punt C.J.A., Iannotti N., et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009, 20:1223-1229.
78. Tol J., Koopman M., Miller M.C., et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2010, 21:1006-1012.
79. Sastre J., Maestro M.L., Gómez-España A., et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish cooperative group for the treatment of digestive tumors study. Oncologist 2012, 17:947-955.
80. Nishizaki T., Matsumata T., Kanematsu T., Yasunaga C., Sugimachi K. Surgical manipulation of VX2 carcinoma in the rabbit liver evokes enhancement of metastasis. J Surg Res 1990, 49:92-97.
81. Weitz J., Koch M., Kienle P., et al. Detection of hematogenic tumor cell dissemination in patients undergoing resection of liver metastases of colorectal cancer. Ann Surg 2000, 232:66-72.
82. Patel H., Le Marer N., Wharton R.Q., et al. Clearance of circulating tumor cells after excision of primary colorectal cancer. Ann Surg 2002, 235:226-231.
83. Koch M., Kienle P., Hinz U., et al. Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg 2005, 241:199-205.
84. Atkin G., Chopada A., Mitchell I. Colorectal cancer metastasis: in the surgeon's hands?. Int Semin Surg Oncol 2005, 2:5-12.
85. Van Cutsem E., Nordlinger B., Adam R., et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006, 42:2212-2221.
86. Bismuth H. Surgical anatomy and anatomical surgery of the liver. World J Surg 1982, 6:3-9.
87. Schmidt T., Koch M., Antolovic D., et al. Influence of two different resection techniques (conventional liver resection versus anterior approach) of liver metastases from colorectal cancer on hematogenous tumor cell dissemination - prospective randomized multicenter trial. BMC Surg 2008, 8:6.
88. Tralhão J.G., Hoti E., SerÔdio M., et al. Perioperative tumor cell dissemination in patients with primary or metastatic colorectal cancer. Eur J Surg Oncol 2010, 36:125-129.
89. Gutt C.N., Riemer V., Kim Z.G., et al. Impact of laparoscopic colonic resection on tumour growth and spread in an experimental model. Br J Surg 1999, 86:1180-1184.
90. Lee W.S., Yun S.H., Chun H.K., et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol 2008, 42:945-949.
91. Abdalla E.K., Vauthey J.N., Ellis L.M., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004, 239:818-825.
92. Jiao L.R., Apostolopoulos C., Jacob J., et al. Unique localization of circulating tumor cells in patients with hepatic metastases. J Clin Oncol 2009, 27:6160-6165.
93. Gleisner A.L., Choti M.A., Assumpcao L., et al. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 2008, 143:1204-1212.
94. Eisele R.M., Neumann U., Neuhaus P., et al. Open surgical is superior to percutaneous access for radiofrequency ablation of hepatic metastases. World J Surg 2009, 33:804-811.
95. Hong S.N., Lee S.Y., Choi M.S., et al. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 2005, 39:247-252.
96. Molinari M., Helton S. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. Am J Surg 2009, 198:396-406.
97. de la Haba-Rodriguez J.R., Ruiz Borrego M., Gomez Espana A., et al. Comparative study of the immunohistochemical phenotype in breast cancer and its lymph node metastatic location. Cancer Invest 2004, 2:219-224.
98. Gangnus R., Langer S., Breit E., Pantel K., Speicher M.R. Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res 2004, 10:3457-3464.
99. Klein C.A., Blankenstein T.J., Schmidt-Kittler O., et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002, 9334:683-689.
100. Lie'vre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
101. Di Fiore F., Blanchard F., Charbonnier F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007, 96:1166-1169.
102. Khambata-Ford S., Garrett C.R., Meropol N.J., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25:3230-3237.
103. De Roock W., Piessevaux H., De Schutter J., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19:508-515.
104. Lie'vre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379.
105. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
106. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
107. Sartore-Bianchi A., Di Nicolantonio F., Nichelatti M., et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4:e7287.
108. Artale S., Sartore-Bianchi A., Veronese S.M., et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008, 26:4217-4219.
109. Etienne-Grimaldi M.-C., Formento J.-L., Francoual M., et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008, 14:4830-4835.
110. Chen Y.F., Wang J.Y., Wu C.H., Chen F.M., Cheng T.L., Lin S.R. Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett 2005, 229:115-122.
111. Di Fiore F., Charbonnier F., Lefebure B., et al. Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. Br J Cancer 2008, 99:551-552.
112. Yen L.C., Yeh Y.S., Chen C.W., et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2009, 15:4508-4513.
113. Gasparini G., Longo R., Torino F., Gattuso D., Morabito A., Toffoli G. Is tailored therapy feasible in oncology?. Crit Rev Oncol Hematol 2006, 57:79-101.
114. Gangadhar T., Schilsky R.L. Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol 2010, 7:318-325.
115. Gazzaniga P., Gradilone A., Petracca A., et al. Molecular markers in circulating tumor cells from metastatic colorectal cancer patients. J Cell Mol Med 2010, 14:2073-2077.
116. Boman B.M., Wicha M.S. Cancer stem cells: a step toward the cure. J Clin Oncol 2008, 26:2795-2799.
117. Boman B.M., Wicha M.S., Fields J.Z., Runquist O.A. Symmetric division of cancer stem cells-a key mechanism in tumor growth that should be targeted in future therapeutic approaches. Clin Pharmacol Ther 2007, 81:893-898.
118. Zhang M., Rosen J.M. Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev 2006, 16:60-64.
119. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
120. Carney D.N., Gazdar A.F., Bunn P.A., et al. Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients. Stem Cells 1982, 1:149-164.
121. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
122. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., et al. Identification and expansion of human colon cancer-initiating cells. Nature 2007, 445:111-115.
123. Todaro M., Francipane M.G., Medema J.P., Stassi G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010, 138:2151-2162.
124. Ricci-Vitiani L., Fabrizi E., Palio E., De Maria R. Colon cancer stem cells. J Mol Med 2009, 87:1097-1104.
125. Barker N., Ridgway R.A., van Es J.H., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611.
126. Du J., Li Y., Li J., Zheng J. Polycomb group protein Bmi1 expression in colon cancers predicts the survival. Med Oncol 2009, 27:1273-1276.
127. Dalerba P., Dylla S.J., Park I.K., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007, 104:10158-10163.
128. Al-Hajj M., Wicha M.S., Benito-Hernandez A., et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
129. Patrawala L., Calhoun T., Schneider-Broussard R., et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25:1696-1708.
130. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
131. Pang R., Law W.L., Chu A.C., et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010, 6:603-615.
132. Brabletz T., Jung A., Spaderna S., et al. Migrating cancer stem cells: an integrated concept of malignant tumour progression. Nat Rev Cancer 2005, 5:744-749.
133. Fodde R., Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Nat Rev Cancer 2005, 5:745-749.
134. Brabletz S., Schmalhofer O., Brabletz T. Gastrointestinal stem cells in development and cancer. J Pathol 2009, 217:307-317.
135. Theodoropoulos P.A., Polioudaki H., Agelaki S., et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010, 288:99-106.
136. Iinuma H., Watanabe T., Mimori K., et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 2011, 29:1547-1555.
137. Shimada R., Iinuma H., Akahane T., Horiuchi A., Watanabe T. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients. Oncol Rep 2012, 27:947-953. 10.3892/or.2012.1649.
138. Nakamura K., Iinuma H., Aoyagi Y., Shibuya H., Watanabe T. Predictive value of cancer stem-like cells and cancer-associated genetic markers for peritoneal recurrence of colorectal cancer in patients after curative surgery. Oncology 2010, 78:309-315.
139. Zheng S., Lin H., Liu J.Q., et al. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr 2007, 1162:154-161.
140. Steinert G., Schölch S., Koch M., Weitz J. Biology and significance of circulating and disseminated tumour cells in colorectal cancer. Langenbecks Arch Surg 2012, 397:535-542.
141. Pantel K., Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 2010, 16:398-406.
142. Mostert B., Sleijfer S., Foekens J.A., Gratama J.W. Circulating tumor cells: detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 2009, 35:463-474.
143. Lankiewicz S., Rivero B.G., Böcher O. Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment. Mol Biotechnol 2006, 34:15-27.
144. Kraeft S.K., Sutherland R., Gravelin L., et al. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin Cancer Res 2000, 6:434-442.
145. Mansi J.L., Mesker W.E., McDonnell T., et al. Automated screening for micrometastases in bone marrow smears. J Immunol Methods 1988, 112:105-111.
146. Mesker W.E., van der Burg J.B., Oud P.S., et al. Detection of immunocytochemically stained rare events using image analysis. Cytometry 1994, 17:209-215.
147. Mikulova V., Kološtova K., Zima T. Methods for detection of circulating tumour cells and their clinical value in cancer patients. Folia Biol 2011, 57:151-161.
148. Ntouroupi T.G., Ashraf S.Q., McGregor S.B., et al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer 2008, 99:789-795.
149. Baker M.K., Mikhitarian K., Osta W., et al. Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology. Clin Cancer Res 2003, 9:4865-4871.
150. Miltenyi S., Muller W., Weichel W., Radbruch A. High gradient magnetic cell separation with MACS. Cytometry 1990, 11:231-238.
151. Martin V.M., Siewert C., Scharl A., et al. Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS. Exp Hematol 1998, 26:252-264.
152. Talasaz A.H., Powell A.A., Huber D.E., et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA 2009, 106:3970-3975.
153. Naume B., Borgen E., Tøssvik S., et al. Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method. Cytotherapy 2004, 6:244-252.
154. Alix-Panabières C., Vendrell J.P., Pellé O., et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007, 53:537-539.
155. Lu J., Fan T., Zhao Q., et al. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer 2010, 126:669-683.
156. Vona G., Sabile A., Louha M., et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 2000, 156:57-63.
157. Gascoyne P.R., Noshari J., Anderson T.J., Becker F.F. Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis 2009, 30:1388-1398.
158. Tan S.J., Lakshmi R.L., Chen P., Lim W.T., Yobas L., Lim C.T. Versatile label free biochip for the detection of circulating tumor cells from peripheral blood in cancer patients. Biosens Bioelectron 2010, 26:1701-1705.
159. Taniguchi T., Makino M., Suzuki K., Kaibara N. Prognostic significance of reverse transcriptase-polymerase chain reaction measurement of carcinoembryonic antigen mRNA levels in tumor drainage blood and peripheral blood of patients with colorectal carcinoma. Cancer 2000, 89:970-976.
160. Yamaguchi K., Takagi Y., Aoki S., Futamura M., Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase polymerase chain reaction during colorectal cancer resection. Ann Surg 2000, 232:58-65.
161. Douard R., Wind P., Sales J.P., et al. Long-term prognostic value of detection of circulating colorectal cancer cells using CGM2 reverse transcriptase-polymerase chain reaction assay. Surgery 2006, 139:556-562.
162. Katsumata K., Sumi T., Mori Y., et al. Detection and evaluation of epithelial cells in the blood of colon cancer patients using RT-PCR. Int J Clin Oncol 2006, 11:385-389.
163. Yie S.M., Lou B., Ye S.R., et al. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol 2008, 15:3073-3082.
164. Hardingham J.E., Hewett P.J., Sage R.E., et al. Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer 2000, 89:8-13.
165. Kanellos I., Zacharakis E., Kanellos D., et al. Prognostic significance of CEA levels and detection of CEA mRNA in draining venous blood in patients with colorectal cancer. J Surg Oncol 2006, 94:3-8.
166. Wang J.Y., Lin S.R., Wu D.C., et al. Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin Cancer Res 2007, 13:2406-2413.
167. Uen Y.H., Lin S.R., Wu D.C., et al. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann Surg 2007, 246:1040-1046.
168. Matsusaka S., Suenaga M., Mishima Y., et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. Cancer Sci 2011, 102:1188-1192.
169. Aggarwal C., Meropol N.J., Punt C.J., et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol 2012, 10.1093/annonc/mds336.
170. Papavasiliou P., Fisher T., Kuhn J., Nemunaitis J., Lamont J. Circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Proc (Bayl Univ Med Cent) 2010, 23:11-14.
171. Pilati P., Mocellin S., Bertazza L., et al. Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann Surg Oncol 2012, 19:402-408.